Targets of immunotherapy are distinct molecules or pathways that allow the immune system to recognize and kill cancer cells effectively. The session "Immunotherapy Targets" is dedicated to discovering, understanding, and utilizing these targets for creating new cancer therapies.".
These targets include immune checkpoints, tumor-associated antigens, neoantigens, and cytokine pathways involved in immune activation and suppression. By modulating these targets, therapies like checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines are able to optimize anti-tumor immunity without damaging normal tissues. It is important to understand the tumor-specific antigens and immune evasion mechanisms in order to design personalized and effective immunotherapeutic approaches.
The session examines strategies to recognize new targets by genomic profiling, proteomics, and bioinformatics analysis. Integration of biomarker-guided approaches enables clinicians to forecast patient response, track treatment efficiency, and modify therapy accordingly. Combination therapies for multiple pathways are becoming a strategy for overcoming resistance and enhancing clinical outcomes.
Participants will learn about the biology, clinical significance, and translational utility of immunotherapy targets. This session highlights how precise targeting of immune mechanisms is revolutionizing cancer treatment, improving treatment effectiveness, and driving personalized oncology for improved patient outcomes.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
